Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 355 participants.
Also called NCT02791763
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 355 participants
- Sponsor
- Registry
-
NCT02791763
-
- Other papers using this trial's data
- Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02791763. Randomized; no masking; primary purpose treatment. Start 2016-06-06 (actual); primary completion 2018-10-26 (actual). Results posted on 2019-11-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
- Condition
- Anaemia
- Intervention (Drug)
- 1 to 4 mg tablets of GSK1278863
- Intervention (Drug)
- 6 mg GSK1278863 tablet
- Intervention (Drug)
- Epoetin beta pegol
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct02791763- Content hash
deeadef1aa503de39e3923b38d2aa155020da6b0a8439802cfb95c70c8920e80